No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. Nifurtimox appears to be biotransformed partially at a cytochrome P450 level but mostly by NADPH P450 reductase, with less than 1% of a dose excreted unchanged via the kidneys. There is little potential for an interaction with emtricitabine and tenofovir due to competition for renal elimination pathways.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking